Shield Therapeutics plc’s (STX) “Buy” Rating Reaffirmed at FinnCap
Shield Therapeutics plc (LON:STX)‘s stock had its “buy” rating reiterated by equities researchers at FinnCap in a research note issued to investors on Tuesday. They presently have a GBX 265 ($3.49) target price on the stock. FinnCap’s price objective points to a potential upside of 94.14% from the company’s current price.
A number of other research firms also recently weighed in on STX. Peel Hunt reissued a “buy” rating and set a GBX 220 ($2.89) target price on shares of Shield Therapeutics plc in a research report on Wednesday, November 8th. Liberum Capital reissued a “buy” rating and set a GBX 245 ($3.22) target price on shares of Shield Therapeutics plc in a research report on Tuesday, October 10th.
Shield Therapeutics plc (LON:STX) traded down GBX 10 ($0.13) during trading hours on Tuesday, reaching GBX 136.50 ($1.80). 6,463 shares of the company’s stock were exchanged, compared to its average volume of 2,815. Shield Therapeutics plc has a twelve month low of GBX 143 ($1.88) and a twelve month high of GBX 173.50 ($2.28).
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.